Focused On-demand Library for Adrenocortical dysplasia protein homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96AP0

UPID:

ACD_HUMAN

Alternative names:

POT1 and TIN2-interacting protein

Alternative UPACC:

Q96AP0; A0A0C4DGT6; Q562H5; Q9H8F9

Background:

The Adrenocortical dysplasia protein homolog, also known as POT1 and TIN2-interacting protein, plays a crucial role in telomere maintenance. As a component of the shelterin complex, it regulates telomere length and protection, ensuring chromosome ends are shielded from DNA damage surveillance. Its interaction with POT1 and modulation of telomere elongation are vital for cellular longevity and genomic stability.

Therapeutic significance:

Dyskeratosis congenita, both autosomal dominant and recessive forms, are linked to mutations in this protein, highlighting its critical role in telomere maintenance disorders. Understanding the Adrenocortical dysplasia protein homolog could pave the way for innovative treatments targeting bone marrow failure, pulmonary fibrosis, and other telomere-related conditions.